Pharmacological and non pharmacological Management of ADHD with mixed borderline and narcissistic personality disorder with excessive sexual desire and impulsivity for multiple sexual partners

Reading File
Finding Sources
Finding Sources
Finding Sources
Searching PubMed

ADHD borderline personality disorder comorbidity treatment

Finding Sources
Finding Sources
Reading Article

PMID: 38002478

Reading Article

PMID: 41667836

Reading File
Reading File
Finding Sources
Searching PubMed

hypersexuality compulsive sexual behavior pharmacological treatment

Finding Sources
Finding Sources
Reading Article

PMID: 41426818

Reading Article

PMID: 40141725

Reading File
Finding Sources
Searching the Web

ADHD borderline narcissistic personality disorder comorbidity management guidelines 2024 2025

Here is a thorough, evidence-based overview of the management of this complex comorbid presentation: ADHD + mixed borderline (BPD) and narcissistic personality disorder (NPD) + compulsive/hypersexual behavior with sexual impulsivity.

Management of ADHD with Mixed BPD/NPD and Hypersexual Impulsivity

1. Diagnostic Framing and Clinical Priorities

This triad represents one of the most challenging presentations in adult psychiatry. Several core principles apply before initiating treatment:
  • Establish diagnostic clarity first. ADHD and BPD share overlapping features (emotional dysregulation, impulsivity, rejection sensitivity). A careful longitudinal history is required to distinguish trait-based personality pathology from state-dependent ADHD symptoms. NPD traits may overlay both.
  • Hypersexuality and compulsive multi-partner seeking in this context arise from several converging mechanisms: ADHD-related dopaminergic novelty-seeking and impulsivity, BPD-driven emotional dysregulation and fear of abandonment (sexuality used to regulate affect or gain validation), and NPD-driven entitlement and grandiosity.
  • Suicide/self-harm risk must be assessed continuously - BPD carries a markedly elevated suicide mortality.
  • Stabilize personality disorder first, then address ADHD symptoms - this is the recommended sequencing (MacDonald & Sadek, Brain Sci 2023, PMID 38002478).

2. Psychotherapy (Non-Pharmacological) - First-Line Priority

A. Dialectical Behavior Therapy (DBT) - PRIMARY treatment

DBT is the gold standard, evidence-based psychotherapy for BPD and directly addresses the core problems here:
  • Skills modules: distress tolerance, emotion regulation, interpersonal effectiveness, mindfulness
  • Reduces self-destructive impulsivity, suicidality, and self-injurious behavior
  • Highly applicable to sexual impulsivity - DBT's "urge surfing" and chain analysis directly target compulsive sexual acting-out
  • Individual DBT + skills training group is the full model; adapted formats exist in community settings
  • Goldman-Cecil Medicine, p. 2615; Kaplan & Sadock's Comprehensive Textbook, block 39

B. Mentalization-Based Treatment (MBT)

Developed specifically for BPD, MBT addresses the impaired ability to understand one's own and others' mental states - directly relevant to:
  • Narcissistic interpersonal exploitation (uses others for gratification without mentalizing their experience)
  • Sexual acting-out driven by failure to reflect on consequences
  • Comparable outcomes to DBT for BPD overall
  • Kaplan & Sadock's Comprehensive Textbook, "Mentalization-Based Treatment of BPD," block 38

C. Transference-Focused Psychotherapy (TFP)

Psychoanalytic approach particularly suited for NPD:
  • Addresses grandiosity, entitlement, and the shallow/idealization-devaluation cycle
  • Works through distorted relational patterns directly in the therapeutic relationship
  • Requires a stable outpatient frame; higher-functioning patients benefit most

D. Psychodynamic/Psychoanalytic Psychotherapy for NPD

  • NPD is challenging to treat because progress requires patients to relinquish narcissism
  • Group therapy adjunct can build empathy and reduce exploitative patterns (Kaplan & Sadock's Synopsis, p. 1714)
  • A 2024 study found ADHD pharmacotherapy (psychostimulants) improved empathy deficits and reduced narcissistic pathology as an additional benefit (Takım et al., Alpha Psychiatry 2024)

E. CBT adapted for ADHD (CBT-A)

  • Targets ADHD-specific deficits: time management, organization, procrastination
  • Can be integrated with DBT work; cognitive restructuring for impulsive decision-making applies directly to sexual behavior patterns
  • Psychoeducation about ADHD and personality disorders reduces shame and improves engagement

F. Sex therapy / psychosexual psychotherapy

  • Compulsive sexual behavior disorder (CSBD) should be assessed formally (ICD-11 diagnosis)
  • Motivational enhancement + CBT model for CSBD addresses triggers, high-risk situations, relapse prevention
  • Attachment-based work is essential given BPD abandonment fears driving sexual behavior

G. Schema therapy

Useful for the mixed BPD/NPD presentation - addresses early maladaptive schemas (abandonment, entitlement, subjugation) that underlie both personality disorders

H. Psychoeducation, Lifestyle, and Adjuncts

  • Sleep hygiene (poor sleep worsens ADHD and emotional dysregulation)
  • Regular aerobic exercise - strong evidence for ADHD symptom reduction; reduces impulsivity
  • Mindfulness-based interventions (MBSR, MBCT) as adjuncts
  • Structured daily routines; external scaffolding (planners, alarms) for ADHD
  • Avoiding high-stimulation environments and substance use (markedly increases sexual impulsivity)

3. Pharmacological Management

Sequencing Principle

Step 1: Stabilize mood/emotional dysregulation (personality disorder layer) Step 2: Address residual ADHD symptoms Step 3: Target specific problem behaviors (sexual impulsivity)

A. Medications for BPD/NPD Symptoms

Mood Stabilizers (for emotional dysregulation, impulsivity, aggression)

DrugEvidenceNotes
Lamotrigine 50-200 mg/dayHigh-quality (network meta-analysis 2026)Best evidence for hostility, anger, impulsivity; generally well-tolerated
Topiramate 200-250 mg/dayHighest level of evidenceReduces hostility and aggression; cognitive side effects (word-finding) limit use; weight-neutral (useful if BED comorbid)
Carbamazepine 200-1200 mg/dayLow-moderateImproves impulsivity; drug interactions and teratogenicity limit use
ValproateLow certainty in unselected BPDAvoid as first-line; limited evidence
LithiumUseful for NPD with mood swingsAlso helpful for NPD-associated mood instability (Kaplan & Sadock's Synopsis, p. 1714)
Source: Gerolymos et al., Mol Psychiatry 2026, PMID 41667836 - network meta-analysis of 35 RCTs, 2551 participants

Second-Generation Antipsychotics (for crisis stabilization, emotional dysregulation, brief psychotic episodes)

DrugEvidenceNotes
Aripiprazole 15 mg/dayModerate (network meta-analysis 2026)Reduces hostility/anger; partial dopamine agonist may be advantageous with ADHD dopaminergic dysregulation
Asenapine 5-10 mg/dayLow (but improves emotional dysregulation)Sublingual; metabolic monitoring needed
QuetiapineWidely used clinicallyLow doses (25-100 mg) for sleep, anxiety, crisis stabilization
Avoid: HaloperidolLow-certainty, older evidence onlyUse only in acute emergency
Note on antipsychotics for NPD: Antipsychotics can help with anger outbursts, paranoid ideation, and brief psychotic features that occur in cluster B disorders under stress (Kaplan & Sadock's Synopsis; Goldman-Cecil Medicine, p. 2617).

Antidepressants (for comorbid depression, rejection sensitivity, anxiety)

  • SSRIs (fluoxetine, sertraline): helpful for depressed mood in BPD, rejection sensitivity in NPD; some evidence for reducing impulsive aggression
  • SNRIs (venlafaxine): useful if prominent anxiety/depression comorbidity
  • Bupropion: norepinephrine-dopamine reuptake inhibitor - has dual utility as an ADHD-adjacent agent AND antidepressant (discussed below)
  • Benzodiazepines should be avoided due to disinhibition risk and abuse potential in BPD/ADHD (Kaplan & Sadock's Synopsis)

B. Medications for ADHD (added after personality disorder stabilization)

Stimulants (first-line for ADHD)

DrugNotes for this comorbidity
Methylphenidate (immediate or extended-release)May reduce impulsivity in BPD+ADHD; real-world data show reduced suicidality in BPD (Pardossi et al., Life 2025, PMID 40141725); start low, titrate carefully
Lisdexamfetamine (Vyvanse)Longer duration, lower abuse potential; approved for binge eating disorder as well (relevant if impulsive eating comorbidity)
Amphetamine salts (mixed amphetamine)Effective for ADHD; monitor for emotional intensification
Key caution: Stimulants may initially destabilize BPD emotional reactivity. The 2026 network meta-analysis explicitly states methylphenidate has low-certainty evidence in unselected BPD and should be reserved for confirmed comorbid ADHD with cautious clinical appraisal (PMID 41667836). When ADHD is confirmed and personality is stabilized, stimulants can be beneficial.
A 2024 study (Takım et al.) found psychostimulant treatment in adult ADHD improved empathy deficits and reduced narcissistic pathology - an important additional benefit in this population.

Non-Stimulant ADHD Medications (preferred when stimulant risk outweighs benefit)

DrugNotes
Atomoxetine (Strattera)NRI; lower abuse potential; useful when substance misuse risk exists; improves emotional dysregulation as well as inattention; may reduce rejection sensitivity
Bupropion (Wellbutrin)NDRI; antidepressant + ADHD effects; useful in BPD/NPD with depression; also may reduce hypersexual urges (some evidence as anti-compulsive agent)
Clonidine / Guanfacine (alpha-2 agonists)Reduce hyperactivity/impulsivity; clonidine useful for insomnia and hyperarousal; lower evidence base in adults but helpful adjuncts
Viloxazine (Qelbree)Novel NRI; emerging adult ADHD data; may be considered when tolerability is a concern

C. Addressing Sexual Compulsivity/Hypersexuality

Pharmacological Targets

DrugRationaleEvidence
SSRIs (especially high-dose fluoxetine, sertraline, or paroxetine)Reduce sexual drive and compulsive urges via serotonergic mechanisms; first-line for CSBDModerate clinical evidence; widely used
Naltrexone 50-100 mg/dayOpioid antagonist - reduces reward salience of sexual acting-out; used for behavioral addictionsEvidence in alcohol use disorder, gambling; limited but promising in CSBD
BupropionAs above - may reduce hypersexual urges while treating ADHD/depressionUseful overlapping target
Anti-androgens (e.g., cyproterone acetate, medroxyprogesterone)Reduce testosterone-driven libido; reserved for severe, treatment-resistant casesSignificant side effects; generally last resort
GnRH analogues (leuprolide)Strong libido suppression; used in very severe/forensic casesSpecialist only; significant side effects
Mood stabilizers (lamotrigine, topiramate)By reducing overall impulsivity, indirectly reduce sexual impulsivityDual benefit in this combination
Note: The ICD-11 recognized CSBD (Compulsive Sexual Behavior Disorder) as a distinct diagnosis. The Italian SIAMS/SOPSI consensus statement (PMID 35527295, 2022) specifically recommends evaluating hypersexuality as potentially secondary to ADHD, mood disorders, or personality disorders - treatment of the underlying condition is the primary approach.
ADHD hypersexuality often involves "dopaminergic craving" and novelty-seeking. The 2025 review on ADHD and sexual functioning (Puszcz et al., PMID 41426818) highlights that:
  • Psychostimulants (methylphenidate, lisdexamfetamine) and nonstimulants (atomoxetine, clonidine) have both beneficial and adverse sexual effects
  • ADHD-related sexual risk behaviors are driven by rejection-sensitive dysphoria (RSD), impaired inhibitory control, and the need for hyperfocus experiences
  • Interdisciplinary management combining pharmacotherapy and psychotherapy targeting emotional regulation is recommended

4. Integrated Treatment Framework

Phase 1 - Safety, Engagement, Diagnosis (weeks 1-8)
├── Full diagnostic workup (ADHD rating scales, structured PD interview)
├── Risk assessment (suicide, STI/HIV from multiple partners, substance use)
├── Psychoeducation about all three diagnoses
└── Start DBT skills group + individual therapy referral

Phase 2 - Stabilization (months 2-6)
├── Initiate mood stabilizer (lamotrigine preferred) OR SSRI
├── Add antipsychotic only if crisis, brief psychosis, or severe aggression
├── Address sexual compulsivity in therapy; consider SSRI/naltrexone
└── Continue DBT; begin motivational work on sexual behavior

Phase 3 - ADHD Treatment (after Phase 2 stability)
├── Add atomoxetine (preferred first) or low-dose stimulant
├── Monitor for emotional destabilization
└── Titrate based on response; bupropion as alternative

Phase 4 - Consolidation (months 6+)
├── Maintain medication regimen with regular review
├── Long-term psychotherapy (TFP or schema therapy for NPD)
├── Sex therapy / CSBD-focused psychotherapy
└── Relapse prevention for sexual impulsivity

5. Special Considerations and Cautions

  • Avoid benzodiazepines - high disinhibition and abuse risk in this population
  • Substance use screening is mandatory - ADHD + BPD have markedly elevated SUD rates, which will undermine all other treatment
  • Sexual health: screen for STIs, discuss contraception/reproductive health given multiple partners
  • Prescriber-patient relationship: BPD patients may idealize/devalue the prescriber; consistent, boundaried, non-reactive prescribing stance is essential
  • No FDA-approved medication exists for BPD or NPD - all pharmacotherapy is symptom-targeted and adjunctive to psychotherapy
  • Forensic/ethical considerations: if sexual behavior involves coercion or minors, mandatory reporting obligations apply
  • Stimulant misuse potential should be assessed; consider urine drug screens if indicated

Key References

  1. Gerolymos et al. (2026) - Network meta-analysis, BPD pharmacotherapy, Mol Psychiatry, PMID 41667836 (35 RCTs, 2551 patients - highest quality evidence available)
  2. MacDonald & Sadek (2023) - ADHD + BPD/BD management review, Brain Sci, PMID 38002478
  3. Pardossi et al. (2025) - Methylphenidate in BPD, Life, PMID 40141725
  4. Puszcz et al. (2025) - ADHD and sexual functioning, Cureus, PMID 41426818
  5. APA Practice Guideline for BPD (2024) - Updated guidelines emphasizing psychotherapy-first, conservative prescribing, and comorbidity review before medication
  6. Kaplan & Sadock's Synopsis of Psychiatry - NPD and BPD pharmacotherapy, p. 1714
  7. Goldman-Cecil Medicine - Personality disorder treatment, p. 2615-2617

Bottom line: Psychotherapy (DBT primarily) is the backbone of treatment. Pharmacotherapy for this comorbid triad follows a staged approach: mood stabilize the BPD layer first (lamotrigine or topiramate have the strongest evidence), then address ADHD (atomoxetine or cautious stimulant use), with SSRIs and/or naltrexone targeting sexual compulsivity. This combination requires coordinated, interdisciplinary care with ongoing risk monitoring.The response above synthesizes the most current evidence (including a 2026 network meta-analysis and the 2024 APA Practice Guideline for BPD) with authoritative textbook content. A few practical clinical notes worth emphasizing:
The most important single decision is sequencing - trying to treat ADHD with stimulants before stabilizing the BPD/NPD layer often fails and can worsen emotional instability. DBT must be established concurrently with any pharmacological approach.
For the sexual impulsivity specifically, the mechanism matters: in ADHD it reflects dopaminergic reward dysregulation + impaired inhibitory control; in BPD it reflects emotion regulation deficits and fear of abandonment; in NPD it reflects entitlement and grandiosity. The treatment must address all three pathways - pharmacologically (SSRI + mood stabilizer + ADHD medication) and psychotherapeutically (DBT skills + psychosexual work + schema/TFP for the NPD layer).

Questions to assess for schizotypal personality disorder

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
I now have everything needed to build a thorough, clinically organized set of assessment questions. Here is the complete guide:

Clinical Interview Questions to Assess for Schizotypal Personality Disorder

Schizotypal PD (Cluster A) is defined by pervasive social/interpersonal deficits combined with cognitive-perceptual distortions and eccentric behavior, without meeting the threshold for psychosis. Assessment requires probing each of the 9 DSM-5 criteria (5 or more required), using open, non-leading questions that allow the patient to reveal their experience in their own words.
Note on interviewing: Taking a history may be difficult - patients often communicate in a distinctive, peculiar manner that needs interpretation. Allow pauses, tolerate vague answers, and gently probe further rather than supplying words.

DSM-5 Criterion 1 - Ideas of Reference (not delusions)

The patient perceives neutral events as having special personal meaning - but retains some insight that this may not literally be true.
  • "Have you ever noticed that things around you - things on TV, in newspapers, or things people say in public - seem to have a special message meant just for you?"
  • "When you walk into a room and people are talking, do you sometimes feel they might be talking about you specifically, even if you're not sure?"
  • "Have you had the sense that certain events or coincidences were somehow connected to you personally?"
  • "Do numbers, colours, or patterns ever seem to carry a hidden meaning for you?"

DSM-5 Criterion 2 - Odd Beliefs and Magical Thinking

Beliefs inconsistent with cultural norms - e.g., clairvoyance, telepathy, sixth sense, superstitions that influence behaviour.
  • "Do you believe in things like telepathy, clairvoyance, or being able to sense things before they happen?"
  • "Have you ever felt that you could influence events or other people's thoughts just by thinking about them?"
  • "Are you superstitious? Do you follow rituals or avoid certain things because you believe it will affect outcomes?"
  • "Have you ever felt that you have a sixth sense or a special ability to perceive things others cannot?"
  • "Do you believe in spirits, energies, or forces that interact with your life in a direct way?"

DSM-5 Criterion 3 - Unusual Perceptual Experiences

Illusions (misperceptions of real stimuli), not full hallucinations. Bodily illusions. Sensing presences.
  • "Have you ever had the sense that someone or something was nearby or in the room with you, even when you were alone?"
  • "Have you ever noticed shapes, figures, or shadows out of the corner of your eye that turned out not to be there?"
  • "Do you sometimes feel strange sensations in your body - like your limbs feel different, or you feel disconnected from yourself?"
  • "Have you ever heard your name called, or faint sounds, when no one was there?"
  • "Does your own face or body ever look strange or different to you when you look in the mirror?"

DSM-5 Criterion 4 - Odd Thinking and Speech

Vague, circumstantial, metaphorical, over-elaborate, or stereotyped speech. No formal thought disorder - but communication is distinctly unusual.
(Observe directly during interview - also ask:)
  • "People sometimes tell me I'm hard to follow or that I go off on tangents - has anyone ever said something like that to you?"
  • "Do you ever find it hard to put your thoughts into words in a way that others understand?"
  • "Do people sometimes look confused when you're explaining something, even when it seems clear to you?"
  • "Would you say you tend to think about things in a very detailed or symbolic way that others might find unusual?"
Observe: Is the patient's speech tangential, over-elaborate, or peppered with unusual words or metaphors? Does the patient use private language?

DSM-5 Criterion 5 - Suspiciousness / Paranoid Ideation

Not delusional - but pervasive mistrust and wariness of others' motives.
  • "Do you generally trust people, or do you tend to be cautious because you feel others might have bad intentions toward you?"
  • "Do you often feel that people are trying to take advantage of you, or are acting in ways that could harm you?"
  • "When something goes wrong in your life, do you find yourself wondering if someone did something to cause it?"
  • "Is it hard for you to confide in people because you worry they'll use what you've shared against you?"

DSM-5 Criterion 6 - Inappropriate or Constricted Affect

Emotional responses that seem flat, cold, or strangely mismatched to the context.
(Largely observed - also ask:)
  • "People who know you - would they say you're hard to read emotionally, or that your reactions don't always match the situation?"
  • "Do you feel your emotions are muted, or that you don't feel things as strongly as others seem to?"
  • "Have you been told you seem cold, detached, or not particularly warm with people?"
Observe: Does the patient smile at appropriate moments? Does their tone vary? Is there a flat or oddly cheerful quality when discussing distressing material?

DSM-5 Criterion 7 - Odd, Eccentric, or Peculiar Behavior or Appearance

(Largely observed during the interview. Supplement with questions.)
  • "Would people who know you describe your style - how you dress, how you present yourself - as unusual or different from most people?"
  • "Do you have habits or routines that others might find strange or hard to understand?"
  • "Have you ever been told that your mannerisms or the way you carry yourself is unusual?"
Observe: Unusual clothing choices, unkempt or idiosyncratic appearance, unusual mannerisms, self-referential gestures, mumbling to self.

DSM-5 Criterion 8 - Lack of Close Friends or Confidants

Few or no close friends outside of first-degree family members - not simply due to circumstance.
  • "How many close friends would you say you have - people you can really talk to and trust?"
  • "Have you ever had a close friendship that lasted a long time?"
  • "Do you prefer to spend time alone, or is it more that you'd like connection but it just doesn't happen?"
  • "How do you feel in social situations - parties, group gatherings, workplace events?"

DSM-5 Criterion 9 - Excessive Social Anxiety That Does Not Diminish with Familiarity

Key distinguishing feature from avoidant PD: in schizotypal PD, the anxiety is driven by paranoid fears (about others' intentions), NOT by fear of embarrassment or rejection. It does not lessen as the person becomes more familiar with someone.
  • "When you're around people, do you feel anxious even when you've known them for a while?"
  • "Does being around people you know well feel any different from being around strangers, in terms of your anxiety level?"
  • "When you feel anxious in social situations, what goes through your mind - are you worried about embarrassing yourself, or more that people might have bad intentions toward you?"
  • "Even with family or long-term acquaintances, do you still find yourself on guard or wary?"

Supplementary Probes - Functioning and Longitudinal Course

These contextualise the features and assess chronicity (required for PD diagnosis):
  • "Have you always been like this, or was there a time when things were different?"
  • "Did people at school describe you as an odd or unusual child?"
  • "How has this affected your work or career?"
  • "Have you ever been in a romantic relationship? How did that go?"
  • "Have you ever had times when these experiences became much stronger - where you felt you might be losing touch with reality?"

Red Flags Suggesting Schizotypal PD vs. Schizophrenia

FeatureSchizotypal PDSchizophrenia
DelusionsIdeas of reference (some insight retained)Fixed, true delusions (no insight)
HallucinationsIllusions, perceptual distortions, brief transientPersistent, prominent
Psychotic episodesBrief, fragmentary, often stress-triggeredSustained episodes
Thought disorderAbsent; only odd speechOften present
OnsetStable, lifelong trait patternEpisodic, marked deterioration

Differential Considerations to Probe Specifically

  • Schizoid PD: Schizotypal has magical thinking, perceptual distortions, and odd speech - schizoid does not. Ask about these directly.
  • Paranoid PD: Both are suspicious, but schizotypal adds odd behavior, magical thinking, and perceptual distortions.
  • Autism Spectrum: Schizotypal lacks the repetitive behaviors, early language delays, and restricted interests. Social anxiety in ASD is not paranoid in nature.
  • BPD: BPD has emotional intensity, identity diffusion, and brief psychotic episodes under stress; schizotypal has a more stable eccentric baseline.

Sources: Kaplan & Sadock's Comprehensive Textbook of Psychiatry (block 31); Kaplan & Sadock's Synopsis of Psychiatry (block 7-8, p. 1687, 1699); DSM-5 criteria.

Just summarise the questions to be asked to patient in bullet points

Here are the key assessment questions in bullet points, grouped by domain:

Ideas of Reference

  • Do things on TV, in newspapers, or things people say in public ever seem to have a special message meant just for you?
  • When you walk into a room and people are talking, do you feel they might be talking about you specifically?
  • Have certain events or coincidences ever felt personally connected to you?

Magical Thinking & Odd Beliefs

  • Do you believe in telepathy, clairvoyance, or sensing things before they happen?
  • Have you ever felt you could influence events or others' thoughts just by thinking about them?
  • Are you superstitious, or do you follow rituals to affect outcomes?
  • Do you feel you have a sixth sense or special ability others don't have?

Unusual Perceptual Experiences

  • Have you ever sensed someone or something was nearby when you were alone?
  • Have you seen shapes or shadows out of the corner of your eye that weren't there?
  • Does your own face or body ever look strange to you in the mirror?
  • Have you ever heard your name called when no one was there?

Odd Thinking & Speech

  • Have people told you that you're hard to follow or that you go off on tangents?
  • Do people look confused when you explain something, even when it seems clear to you?
  • Do you think about things in a symbolic or detailed way others find unusual?

Suspiciousness / Paranoid Ideation

  • Do you tend to be cautious because you feel others might have bad intentions toward you?
  • Do you often feel people are trying to take advantage of you?
  • Is it hard to confide in people because you worry they'll use it against you?

Social Anxiety

  • Do you feel anxious around people even after you've known them a long time?
  • Does familiarity with someone reduce your anxiety, or do you stay on guard regardless?
  • When anxious socially, are you worried about embarrassing yourself, or more that others have bad intentions?

Lack of Close Friends

  • How many close friends do you have - people you can truly confide in?
  • Have you ever had a long-lasting close friendship?
  • Do you prefer being alone, or do you want connection but it just doesn't happen?

Odd Behavior & Appearance

  • Would people describe how you dress or present yourself as unusual?
  • Have you been told your habits or mannerisms are strange or hard to understand?

Affect

  • Would others say you're hard to read emotionally, or that your reactions don't match the situation?
  • Have you been told you seem cold or detached?

Longitudinal & Functional

  • Have you always been this way, or was there a time when things were different?
  • Did people at school describe you as odd or unusual?
  • Have you ever been in a romantic relationship, and how did that go?
  • Have you ever felt you might be losing touch with reality during stressful times?

Causes of Tic disorder and it's comorbidities

Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.